This trial tests if a drug can reduce the risk of stroke recurrence.
- Ischemic Stroke
0 Primary · 3 Secondary · Reporting Duration: Up to global targeted endpoint date (approximately 41 months)
2 Treatment Groups
1 of 2
1 of 2
15000 Total Participants · 2 Treatment Groups
Primary Treatment: Milvexian · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Frequently Asked Questions
How much risk is associated with Milvexian usage?
"Our risk assessment yielded Milvexian a score of 3 on the 1-3 scale due to pre-existing data that point towards its efficacy and extensive evidence vouching for its safety." - Anonymous Online Contributor
Are there a range of healthcare facilities performing this clinical test within the state?
"Glendale Adventist Medical Center in Glendale, California, Southland Neurology in Los Alamitos, Colorado and Kaiser Permanente Northern California in Oakland, Delaware are 3 of the 81 enrolment centres for this study." - Anonymous Online Contributor
Are there any open positions for individuals to join this trial?
"According to clinicaltrials.gov, the trial is at present not welcoming new enrolments. This investigation was initially made visible on February 9th 2023 and most recently modified on January 19th 2023. While this particular study has reached its capacity for volunteers, there are still 1303 other trials that need participants now." - Anonymous Online Contributor